natgillin/translations-raw huggingface dataset:
The solid oral extended release pharmaceutical dosage form of anyone of claims 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, pri čemu formulacija matrice s produljenim otpuštanjem nakon što je skladištena pri 25 °C i 60 % relativne vlažnosti zraka barem 1 mjesec daje stupanj otapanja, kad je mjerena u USP uređaju (koš) pri 100 rpm u 900 ml simulirane želučane tekućine bez prisustva enzima (SGF) pri 37 °C, naznačen time da je postotna količina aktivnog agensa oslobođena pri 1, 4 ili 12 sati otapanja koja odstupa ne više od oko 15 % točaka od odgovarajuće in-vitro stupnja otapanja referentne formulacije prije skladištenja.
The solid oral extended release pharmaceutical dosage form of claim 58, wherein the extended release matrix formulation has been stored at 40 °C and 75 % relative humidity (RH). 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 5, naznačen time da je formulacija matrice s produljenim otpuštanjem bila uskladištena pri 40 °C i 75 °C relativne vlažnosti zraka (RH).
The solid oral extended release pharmaceutical dosage form of anyone of claims 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da formulacija matrice s produljenim otpuštanjem nakon što je bila skladištena pri 25 °C i 60% relativne vlažnosti zraka (RH) barem 1 mjesec sadrži količinu od oko jednog aktivnog agensa u % (težinski udio) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem koja odstupa ne više od oko 10 % točaka u odnosu na odgovarajuću količinu aktivnog agensa gledano u % (težinski udio) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem prema referentnoj formulaciji prije skladištenja.
The solid oral extended release pharmaceutical dosage form of claim 60, wherein the extended release matrix formulation has been stored at 40 °C and 75 % relative humidity (RH). 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 7, naznačen time da je formulacija matrice s produljenim otpuštanjem bila skladištena pri 40 °C i 75 % relativne vlažnosti zraka (RH).
Eudragit® RS 30D and Triacetin® are combined while passing through a 60 mesh screen, and mixed under low shear for approximately 5 minutes or until a uniform dispersion is observed. 
Eudragit® RS 30D i Triacein® su kombinirani tijekom prolaženja kroz sito veličine otvora 60 i miješaju se pod niskim smicanjem približno 5 minuta ili sve dok se ne postigne jednolična disperzija.
Oxycodone HCl, lactose, and povidone are placed into a fluid bed granulator/dryer (FBD) bowl, and the suspension sprayed onto the powder in the fluid bed. 
Oksikodon HCL, laktoza i povidon su smješteni u ležište posude fluidnog granulatora/sušila (FBD), a suspenzija je raspršena na prašak u fluidnom ležištu.
The dry granulation is placed in a mixer. 
Suha granulacija je stavljena u mikser.
In the meantime, the required amount of stearyl alcohol is melted at a temperature of approximately 70 °C. 
U međuvremenu, potrebna količina stearil alkohola je otopljena pri temperaturi od približno 70°C.
The melted stearyl alcohol is incorporated into the granulation while mixing. 
Prilikom miješanja se otopljeni stearil alkohol ugrađuje u granulat.
The waxed granulation is transferred to a fluid bed granulator/dryer or trays and allowed to cool to room temperature or below. 
Voštena granulacija je premještena u ležište posude fluidnog granulatora/ sušila ili u plitice i ostavljena da se ohladi na sobnu ili nižu temperaturu.
The waxed granulation is placed in a mixer/blender and lubricated with the required amounts of talc and magnesium stearate for approximately 3 minutes. 
Voštena granulacija se stavi u mikser/miješalicu i podmazuje se s potrebnim količinama talka i magnezijevog stearata otprilike 3 minute.
The granulate is compressed into 125 mg tablets on a suitable tableting machine. 
Granulat se komprimira u 125 mg tablete na pogodnoj mašini za tabletiranje.
The extended release dosage form of claim 12, wherein the composition comprises at least about 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000. 
Oblik doziranja s produljenim otpuštanjem prema zahtjevu 12, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida koji sadrži, bazirano na reološkim mjerenjima, približnu molekulsku težinu od barem 1,000,000.
The extended release dosage form of any one of claims 1 to 12, which is in the form of a tablet formed by direct compression of the composition and cured by at least subjecting said tablet to a temperature of at least about 60 °C or at least about 62 °C for a time period of at least about 1 minute, preferably at least about 5 minutes or at least about 15 minutes. 
Oblik za doziranje s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 23, koji je u obliku tablete napravljene izravnim komprimiranjem sastojka i sušen najmanje podvrgavanjem navedene tablete na temperaturu od barem oko 60°C ili od barem oko 62°C, u vremenskom razdoblju od barem oko 1 minute, poželjno od barem oko 5 minuta ili od barem oko 15 minuta.
A pharmaceutical composition comprising trans-(±)-Δ9-tetrahydrocannabino in the crystalline form and a pharmaceutically-acceptable carrier for use as a medicament. 
Farmaceutski sastav koji sadrži trans-(±)-Δ9-tetrahidrokanabinol u kristalnom obliku i farmaceutski prihvatljiv nosač, naznačen time da se upotrebljava kao lijek.
A pharmaceutical composition comprising trans-(±)-Δ9-tetrahydrocannabinol, wherein said composition is formulated with trans-(±)-Δ9-tetrahydrocannabinol in the crystalline form and a pharmaceutically-acceptable carrier for use as a medicament. 
Farmaceutski sastav koji sadrži trans-(±)-Δ9-tetrahidrokanabinol, naznačen time da je navedeni sastav formuliran s trans-(±)-Δ9-tetrahidrokanabinolom u kristalnom obliku i farmaceutski prihvatljivim nosačem, gdje se farmaceutski sastav upotrebljava kao lijek.
A dosage form comprising a therapeutically effective amount of trans-(±)-Δ9-tetrahydrocannabino in the crystalline form and a pharmaceutically-acceptable carrier for use as a medicament. 
Oblik doziranja koji sadrži terapeutski učinkovitu količinu trans-(±)-Δ9-tetrahidrokanabinola u kristalnom obliku i farmaceutski prihvatljivog nosača za upotrebu kao lijek.
A dosage form comprising a therapeutically effective amount of trans-(±)-Δ9-tetrahydrocannabinol, wherein said dosage form is formulated with trans-(±)-Δ9-tetrahydrocannabinol in the crystalline form for use as a medicament. 
Oblik doziranja koji sadrži terapeutski učinkovitu količinu trans-(±)-Δ9-tetrahidrokanabinola, gdje je navedeni oblik doziranja formuliran s trans-(±)-Δ9-tetrahidrokanabinolom u kristalnom obliku za upotrebu kao lijek.
The pharmaceutical composition or dosage form for use of any one of claims 1-4, wherein the crystalline trans-(±)-Δ9-tetrahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99%, even more preferably at least 99,5% and most preferably at least 99,9% by weight of the total amount of cannabinoids in said composition. 
Farmaceutski sastav ili oblik doziranja za upotrebu prema bilo kojem zahtjevu od 1 do 4, naznačen time da kristalni trans-(±)-Δ9-tetrahidrokanabinol sadrži najmanje 95%, poželjno najmanje 98%, poželjnije najmanje 99%, još poželjnije najmanje 99,5% i najpoželjnije najmanje 99,9% po težini ukupne količine kanabinoida u navedenom sastavu.
The dosage form for use claim 3 or 4, wherein said amount of crystalline trans-(±)-Δ9-tetrahydrocannabinol is 80 mg, 40 mg, 20 mg, 10 mg or 5 mg. 
Oblik doziranja za upotrebu prema zahtjevima 3 ili 4, naznačen time da je navedena količina kristalnog trans-(±)-Δ9-tetrahidrokanabinola 80mg, 40 mg, 20 mg, 10 mg ili 5 mg.
forming a biphasic composition comprising (i) a first organic phase, and (ii) an alcoholic-caustic phase containing the trans-(-)-Δ9-tetrahydrocannabinol and the trans-(+)-Δ9-tetrahydrocannabinol; 
formiranja bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans-(-)-Δ9-tetrahidrokanabinol i trans-(+)-Δ9-tetrahidrokanabinol;
forming a biphasic composition comprising (i) a first organic phase, and (ii) an alcoholic-caustic phase containing trans-(+)-Δ9-tetrahydrocannabinol; 
formiranja bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans-(+)-Δ9-tetrahidrokanabinol;
forming a first biphasic composition comprising (i) a first organic phase, and (ii) an alcoholic-caustic phase containing the trans-(-)-Δ9-tetrahydrocannabinol and the trans-(+)-Δ9-tetrahydrocannabinol; 
formiranja prvog bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans-(-)-Δ9-tetrahidrokanabinol i trans-(+)-Δ9-tetrahidrokanabinol;
separating the alcoholic-caustic phase from the first organic phase; 
separacije alkoholno-kaustične faze od prve organske faze;
forming a second biphasic composition comprising (i) the acid treated alcoholic phase of step (c) and (ii) a second organic phase; 
formiranja drugog bifaznog sastava koji sadrži (i) kiselinom tretiranu alkoholnu fazu iz koraka (c) i (ii) drugu organsku fazu;
contacting the separated second organic phase of step (e) with a non-polar organic solvent to form the first organic composition; or 
dovođenja u kontakt separirane druge organske faze iz koraka (e) s nepolarnim organskim otapalom kako bi se dobio prvi organski sastav; ili
forming a first biphasic composition comprising (i) a first organic phase, and (ii) an alcoholic-caustic phase containing the trans-(+)-Δ9-tetrahydrocannabinol; 
formiranja prvog bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans-(+)-Δ9-tetrahidrokanabinol;
forming a second biphasic composition comprising the acid treated alcoholic phase of step (c) and a second organic phase; 
formiranja drugog bifaznog sastava koji sadrži kiselinom tretiranu alkoholnu fazu iz koraka (c) i drugu organsku fazu;
contacting the separated second organic phase of step (e) with trans-(-)-Δ9-tetrahydrocannabinol and a non-polar organic solvent to form the second organic composition. 
dovođenja u kontakt separirane druge organske faze iz koraka (e) s trans-(-)-Δ9-tetrahidrokanabinolom i nepolarnim organskim otapalom kako bi se dobio drugi organski sastav.
The dosage form for use of claim 11, which is adapted for oral administration, parenteral administration, transmucosal administration, transdermal administration, or administration by inhalation. 
Oblik doziranja za upotrebu prema zahtjevu 11, naznačen time da je prilagođen oralnoj primjeni, parenteralnoj primjeni, transmukoznoj primjeni, transdermalnoj primjeni ili primjeni putem inhalacije.
An oral cannabinoid dosage form comprising a first composition and a second composition, wherein the first composition comprises a therapeutically-effective amount of trans-(±)-Δ9-tetrahydrocannabinol in the crystalline form, and the second composition comprises an effective amount of an agent that is adverse to the pharmacological activity of the trans-(±)-Δ9-tetrahydrocannabinol in the crystalline form, preferably said agent is selected from the group consisting of SR 141716 A, SR 144528, and combinations thereof for use as a medicament. 
Oralni oblik doziranja kanabinoida koji sadrži prvi sastav i drugi sastav, naznačen time da prvi sastav sadrži terapeutski učinkovitu količinu trans-(±)-Δ9-tetrahidrokanabinola u kristalnom obliku, i da drugi sastav sadrži učinkovitu količinu agensa koji je protudjelotvoran na farmakološku aktivnost trans-(±)-Δ9-tetrahidrokanabinola u kristalnom obliku, po mogućnosti navedeni agens je odabran od skupine koja se sastoji od SR 141716 A, SR 144528, i njihovih kombinacija za upotrebu kao lijek.
The oral cannabinoid dosage form of claim 13, wherein said crystalline trans-(±)-A9-tetrahydrocannabinol comprises at least 95% preferably at least 98%, more preferably at least 99%, even more preferably at least 99.5% and most preferably at least 99.9% by weight of the total amount of cannabinoids in said first composition. 
Oralni oblik doziranja kanabinoida prema zahtjevu 13, naznačen time da navedeni kristalni trans-(±)-Δ9-tetrahidrokanabinol sadrži barem 95% poželjno barem 98%, poželjnije barem 99%, još poželjnije barem 99.5% i najpoželjnije barem 99.9% težine ukupne količine kanabinoida u navedenom prvom sastavu.
The oral cannabinoid dosage form of claim 13, wherein the first composition and the second composition are each independently in a form selected from the group consisting of powders, granules, microparticles, multiparticulates, nanoparticles, beads, and mixtures thereof, contained within a capsule; or selected from the group consisting of powders, granules, microparticles, multiparticulates, nanoparticles, and mixtures thereof, dispersed in a pharmaceutically-acceptable matrix. 
Oralni oblik doziranja kanabinoida prema zahtjevu 13, naznačen time da su prvi sastav i drugi sastav svaki neovisno u obliku odabranom iz skupine koja se sastoji od praška, granula, mikročestica, multičestica, nanočestica, kuglica i njihovih smjesa, koji se nalaze unutar kapsule; ili odabranom iz skupine se sastoji od praška, granula, mikročestica, multičestica, nanočestica i njihovih smjesa, disperziranih u farmaceutski prihvatljivoj matrici.
The oral cannabinoid dosage form of claim 13, in the form of a two-layer tablet having a first layer comprising the first composition and a second layer comprising the second composition, wherein the tablet is coated with a coating that dissolves in the stomach. 
Oralni oblik doziranja kanabinoida prema zahtjevu 13, u obliku tablete s dvostrukim slojem gdje prvi sloj sadrži prvi sastav i drugi sloj koji sadrži drugi sastav, naznačen time da je tableta obložena s oblogom koja se otapa u želucu.
A controlled-release, cannabinoid dosage form suitable for 8-hour, 12-hour, or 24 hour dosing in a human patient comprising a pharmaceutically-acceptable matrix comprising a therapeutically-effective amount of trans-(±)-Δ9-tetrahydrocannabino in the crystalline form and a pharmaceutically-acceptable controlled-release material for use as a medicament for oral administration. 
Oblik doziranja kanabinoida s kontroliranim otpuštanjem prikladan za 8-satno, 12-satno, ili 24 satno doziranje kod humanog pacijenta koji sadrži farmaceutski prihvatljivu matricu koja sadrži terapeutski učinkovitu količinu trans-(±)-Δ9-tetrahidrokanabinola u kristalnom obliku i farmaceutski prihvatljivu tvar za kontrolirano otpuštanje za upotrebu kao lijeka za oralnu primjenu.
The controlled-release, cannabinoid dosage form for use of claim 18, wherein the controlled-release material is selected from the group consisting of hydrophobic polymers, hydrophilic polymers, gums, protein-derived materials, waxes, shellacs, oils, and mixtures thereof. 
Oblik doziranja kanabinoida s kontroliranim otpuštanjem za upotrebu prema zahtjevu 18, naznačen time da je tvar za kontrolirano otpuštanje odabrana is skupine koja se sastoji od hidrofobnih polimera, hidrofilnih polimera, guma, tvari koje potječu iz proteina, voskova, šelaka, ulja, i njihovih smjesa.
The controlled-release, cannabinoid dosage form for use of claim 18, said dosage form after administration to a human patient, providing a C24/C max ratio of from 0.55 to 1, preferably from 0.55 to 0.85; more preferably from 0.55 to 0.75; most preferably from 0.60 to 0.70 and said dosage form providing a therapeutic effect for at least 24 hours, wherein C max is preferably a sub-psychotropic-threshold concentration. 
Oblik doziranja kanabinoida s kontroliranim otpuštanjem za upotrebu prema zahtjevu 18, naznačen time da navedeni oblik doziranja nakon primjene na humanom pacijentu, daje C24/Cmax raspon od 0.55 do 1, poželjno od 0.55 do 0.85; poželjnije od 0.55 do 0.75; najpoželjnije od 0.60 do 0.70 i da navedeni oblik doziranja daje terapeutski učinak barem 24 sata, gdje je Cmax poželjno subpsihotropična granična koncentracija.
The controlled-release, cannabinoid dosage form for use of claim 18, wherein said crystalline trans-(±)-Δ9-tetrahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99%, even more preferably at least 99.5% and most preferably at least 99.9% by weight of the total amount of cannabinoids in said dosage form. 
Oblik doziranja kanabinoida s kontroliranim otpuštanjem za upotrebu prema zahtjevu 18, naznačen time da navedeni kristalni trans-(±)-Δ9-tetrahidrokanabinol sadrži barem 95%, poželjno barem 98%, poželjnije barem 99%, još poželjnije barem 99.5% i najpoželjnije barem 99.9% težine ukupne količine kanabinoida u navedenom obliku doziranja.
The dosage form for use of claim 18, wherein said matrix comprises a plurality of multiparticulate matrices, wherein said multiparticulate matrices are preferably compressed into a tablet, disposed in a pharmaceutically-acceptable capsule or disposed in a pharmaceutically-acceptable suspension. 
Oblik doziranja za upotrebu prema zahtjevu 18, naznačen time da navedena matrica sadrži više višečestičnih matrica, gdje su navedene višečestične matrice poželjno kompresirane u tabletu, raspoložive u farmaceutski prihvatljivoj kapsuli ili raspoložive u farmaceutski prihvatljivoj suspenziji.
A process for the preparation of a solid, oral, controlled-release, cannabinoid dosage form according to claim 18 comprising the step of incorporating a therapeutically-effective amount of crystalline trans-(±)-Δ9-tetrahydrocannabinolinto a pharmaceutically-acceptable controlled-release material, wherein the controlled-release material comprises a matrix selected from the group consisting of hydrophobic polymers, hydrophilic polymers, gums, protein-derived materials, waxes, shellacs, oils, and mixtures thereof, forming a controlled-release matrix formulation, said dosage form after administration to a human patient, providing a C24/C max ratio of from 0.55 to 1, preferably from 0.55 to 0.85; more preferably from 0.55 to 0.75 most preferably from 0.60 to 0.70; and a therapeutic effect for at least 24 hours, wherein said trans-(±)-Δ9-tetrahydrocannabinol is present in said dosage form in the crystalline form. 
Postupak za pripremu krutog, oralnog oblika doziranja s kontroliranim otpuštanjem prema zahtjevu 18 koji sadrži korak inkorporirajna terapijski učinkovite količine kristalnog trans-(±)-Δ9-tetrahidrokanabinola u farmaceutski prihvatljivu tvar za kontrolirano otpuštanje, naznačen time da tvar za kontrolirano otpuštanje sadrži matricu odabranu iz skupine koja se sastoji od hidrofobnih polimera, hidrofilnih polimera, guma, tvari koje potječu iz proteina, voskova, šelaka, ulja, i njihovih smjesa, koji formiraju matricu s kontroliranim otpuštanjem, navedeni oblik doziranja nakon primjene na humanom pacijentu, daje C24/Cmax raspon od 0.55 do 1, poželjno od 0.55 do 0.85; poželjnije od 0.55 do 0.75, najpoželjnije od 0.60 do 0.70; i da terapeutski učinak traje barem 24 sata, gdje je navedeni trans-(±)-Δ9-tetrahidrokanabinol u obliku doziranja prisutan u kristalnom obliku.
The process of claim 23, wherein said crystalline trans-(±)-±9-tetrahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99%, even more preferably at least 99.5% and most preferably at least 99.9% by weight of the total amount of cannabinoids in said dosage form. 
Postupak prema zahtjevu 23, naznačen time da navedeni kristalni trans-(±)-Δ9-tetrahidrokanabinol sadrži barem 95%, poželjno barem 98%, poželjnije barem 99%, još poželjnije barem 99.5% i najpoželjnije barem 99.9% težine ukupne količine kanabinoida u navedenom obliku doziranja.
A cannabinoid composition of trans-(±)-Δ9-tetrahydrocannabinol, wherein said composition is formulated with trans-(±)-Δ9-tetrahydrocannabino in the crystalline form and a pharmaceutically-acceptable carrier adapted for transmucosal or transdermal administration for use as a medicament for transmucosal or transdermal administration. 
Kanabinoidni sastav trans-(±)-Δ9-tetrahidrokanabinola, naznačen time da je navedeni sastav formuliran s kristalnim oblikom trans-(±)-Δ9-tetrahidrokanabinola i farmaceutski prihvatljivim nosačem koji je prilagođen za transmukoznu ili transdermalnu primjenu za upotrebu kao lijek za transmukoznu ili transdermalnu primjenu.
The cannabinoid composition for use of claim 25, wherein said crystalline trans-(±)-Δ9-teftahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99%, even more preferably at least 99.5% and most preferably at least 99.9% by weight of the total amount of cannabinoids in said composition. 
Kanabinoidni sastav za upotrebu prema zahtjevu 25, naznačen time da navedeni kristalni trans-(±)-Δ9-tetrahidrokanabinol sadrži barem 95%, poželjno barem 98%, poželjnije barem 99%, još poželjnije barem 99.5% i najpoželjnije barem 99.9% težine ukupne količine kanabinoida u navedenom sastavu.
A use of a therapeutically effective amount of trans-(±)-Δ9-tetrahydrocannabinol in the crystalline form optionally admixed with a pharmaceutically-acceptable carrier, in the production of a medicament, to be administered by deposition of trans-(±)-Δ9-tetrahydrocannabinol into the lungs of a mammal in need thereof. 
Upotreba terapeutski učinkovite količine trans-(±)-Δ9-tetrahidrokanabinola u kristalnom obliku opcionalno pomiješanog s farmaceutski prihvatljivim nosačem, u proizvodnji lijeka, koji bi se primjenjivao taloženjem trans-(±)-Δ9-tetrahidrokanabinola u plućima sisavca kojem je to potrebno.
The use of claim 28, wherein said crystalline trans-(±)-Δ9-tetrahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99%, even more preferably at least 99.5% and most preferably at least 99.9% by weight of the total amount of cannabinoids in said composition. 
Upotreba prema zahtjevu 28, naznačena time da kristalni trans-(±)-Δ9-tetrahidrokanabinol sadrži barem 95%, poželjno barem 98%, poželjnije barem 99%, još poželjnije barem 99.5% i najpoželjnije barem 99.9% težine ukupne količine kanabinoida u navedenom sastavu.
The use of claim 28, wherein said crystalline trans-(±)-Δ9-tetrahydrocannabinol, optionally admixed with a pharmaceutically-acceptable carrier, is in a form selected from the group consisting of powders, granules, microparticles, nanoparticles and mixtures thereof. 
Upotreba prema zahtjevu 28, naznačena time da je navedeni kristalni trans-(±)-Δ9-tetrahidrokanabinol, opcionalno pomiješan s farmaceutski prihvatljivim nosačem, u obliku odabranom iz skupine koja se sastoji od praška, granula, mikročestica, nanočestica i njihovih smjesa.